A Guide to FDA eSTAR Submission Template
eSTAR (electronic Submission Template And Resource) is the FDA’s mandatory interactive PDF template for preparing 510(k) and De Novo medical device submissions. It has been required for most 510(k) submissions since October 1, 2023, and became mandatory for De Novo submissions on October 1, 2025. The current version, eSTAR v6.1 (effective February 16, 2026), includes updated QMSR-aligned content and new Real World Evidence (RWE) sections. eSTAR standardizes submissions into FDA’s preferred review format, reducing incomplete filings and Additional Information (AI) requests.
If you’re preparing a 510(k), De Novo, or PMA submission, understanding the FDA eSTAR submission template correctly — not just downloading it — is what separates a smooth clearance from months of Additional Information requests. This guide covers what’s new in 2026, how to complete the template step by step, review timelines, and where most submitters lose time.
Talk to our experts
What's New in eSTAR for 2026
If you last reviewed eSTAR requirements before 2025, several important changes affect your submission strategy:
- De Novo submissions now require eSTAR — mandatory since October 1, 2025, unless a specific waiver or exemption applies.
- eSTAR Version 6.1 (effective February 16, 2026) updated all three templates — nIVD, IVD, and PreSTAR — to align with QMSR requirements and the FDA’s December 2025 Real World Evidence (RWE) guidance.
- Q-Submissions (Pre-Submissions) are moving toward mandatory eSTAR use as well, under draft FDA guidance — worth monitoring if you regularly hold Pre-Sub meetings with CDRH.
- PreSTAR (for Q-Submissions, informational meetings, and other early-stage requests) remains voluntary but is increasingly recommended by FDA reviewers.
Read Our Blog: FDA Review Process for 510(k) Medical Device Submissions
What Is eSTAR?
eSTAR (electronic Submission Template And Resource) is FDA’s interactive PDF template for assembling premarket medical device submissions — primarily 510(k) and, since October 2025, De Novo requests. It replaced ad hoc PDF and paper-based submissions with a single structured format that mirrors how FDA reviewers actually evaluate a filing.
Unlike a static form, eSTAR is dynamic: fields appear or disappear based on your answers to earlier questions (for example, selecting “Traditional,” “Abbreviated,” or “Special” 510(k) type changes which sections you’re required to complete). This reduces the chance of submitting irrelevant sections or missing required ones.
eSTAR vs. eCopy: What's the Difference?
A question we get often from first-time submitters:
| eSTAR | eCopy (legacy) | |
|---|---|---|
| Format | Interactive, guided PDF | Static PDF/paper copy |
| Validation | Built-in — flags missing fields before submission | None — errors found only after FDA review begins |
| Mandatory for | 510(k) (since Oct 2023), De Novo (since Oct 2025) | Being phased out for most premarket submission types |
| e-Copy validation step | Not required | Required |
If you’re still preparing submissions the old way, this is the single biggest process update to make in 2026.
How to Access and Submit eSTAR for Your Premarket Submission
- Download the correct eSTAR template. FDA provides separate templates for non-IVD devices, IVD devices, and PreSTAR (for early-stage Q-Submissions) — always confirm you have the current version (v6.1 as of this writing) before starting.
- Prepare your submission inside the template. eSTAR’s built-in prompts and guidance fields walk you through device description, predicate comparison, testing data, labeling, and risk management documentation.
- Register for a CDRH Portal account. This is required to submit eSTAR or eCopy premarket submissions online, and registration is open to all applicants.
- Submit through the correct channel. 510(k) and De Novo submissions must go through the CDRH Portal. CBER-regulated products are submitted via FDA’s Electronic Submission Gateway (ESG). Mail submission is still available as a fallback (see FDA’s Document Control Center addresses), but online submission is faster and includes automatic completeness checks.
Tip: Build a parallel internal document (spreadsheet or shared doc) mirroring the eSTAR sections before you open the PDF. It’s much easier to gather and QA your data outside a dynamic form than inside it.
FDA eSTAR Review Timeline
| Review Stage | Standard Timeline | What Happens |
|---|---|---|
| Refuse to Accept (RTA) Review | 15 days | FDA checks whether the submission is complete enough to review |
| Substantive Review | 60 days after RTA | FDA evaluates content and regulatory compliance in depth |
| Decision Letter | ~90 days after substantive review | FDA issues clearance, approval, or additional requirements |
| Additional Information (AI) Response Window | 180 days from request date | Submitter must respond or the submission is placed on hold |
If your eSTAR is incomplete at filing, FDA notifies you by email and places the submission on hold for up to 180 days, or until a corrected eSTAR is resubmitted. After 180 days without a complete resubmission, FDA considers the filing withdrawn.
Common Mistakes That Delay eSTAR Submissions
- Submitting with an outdated template version — always re-download before starting a new submission; FDA updates eSTAR periodically (most recently to v6.1).
- Treating dynamic fields as optional — a field that disappears based on an earlier answer usually means it’s not applicable, not that you can skip it; misreading this is a common RTA rejection cause.
- Weak predicate device comparison — this remains the single most common reason for Additional Information requests, independent of the eSTAR format itself.
- Underestimating file preparation time — first-time eSTAR submitters should budget 2–4 extra weeks compared to legacy formats to account for the learning curve and validation requirements.
- Assuming PreSTAR and eSTAR are the same thing — PreSTAR is for early-stage Q-Submissions and informational meetings; the standard eSTAR is for the actual 510(k)/De Novo/PMA filing.
Benefits of Using eSTAR for Medical Device Submissions
- Fewer incomplete filings — built-in validation catches missing information before you submit, reducing RTA holds.
- Faster, more consistent FDA review — standardized structure means FDA reviewers spend less time hunting for information.
- No separate eCopy validation step, simplifying the submission workflow.
- Improved submission quality — dynamic, guided fields prompt more complete technical and clinical data than open-ended legacy formats.
How Operon Strategist Helps You Navigate FDA eSTAR Submissions
Operon Strategist supports medical device manufacturers, startups, and importers with end-to-end FDA regulatory consulting — including hands-on eSTAR preparation.
✅ FDA 510(k) & De Novo Submission Support — complete eSTAR preparation and review
✅ Regulatory Strategy Development — identifying the correct pathway and predicate strategy before you start filing
✅ Product Feasibility Assessment — technical and regulatory feasibility review before development
✅ Quality Management System Implementation — ISO 13485 and FDA QMSR compliance support
✅ Gap Assessment & Documentation Review — we identify missing documents and technical deficiencies before you submit, not after an RTA hold
Don’t let an incomplete eSTAR cost you a review cycle. Get expert eyes on your submission before it goes to the FDA.
FAQ
Is FDA eSTAR mandatory for FDA 510(k) submissions?
Yes. Since October 1, 2023, eSTAR is mandatory for most FDA 510(k) submissions unless exempted.
What is the purpose of FDA eSTAR Submission?
FDA eSTAR standardizes medical device submissions and improves submission completeness for faster FDA review.
What documents are required for FDA eSTAR Submission?
Typical documents include:
- Device description
- Testing reports
- Labeling
- Risk management files
- Software validation
- Sterility validation
- Predicate comparison
How long does FDA eSTAR review take?
FDA typically performs:
- RTA review within 15 days
- Substantive review within 60 days
- Final decision around 90 days